Glucan functionalized cobalt selenide nanoparticles as well as preparation method and application thereof

Through dextran functional cobalt selenide nanoparticles (Dex@CoSe NPs) targeting biological membranes, the problem of existing antibacterial materials being poor in drug-resistant bacterial biofilms is solved, and effective elimination of inner layer infection and Wound healing promotes.

CN118987252AActive Publication Date: 2024-11-22GUANGDONG HAIYUAN ZHIXIN HEALTH TECHNOLOGY CO LTD

Patent Information

Application Number
CN202411121063.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

The existing antibacterial nanomaterials are not ideal for the biofilm of drug-resistant bacteria, and are difficult to penetrate deep tissues, and cannot effectively eliminate internal biofilm-related infections.

Method used

A dextran functional cobalt selenide nanoparticles (Dex@CoSe NPs) were used to prepare cobalt selenide nanomaterials and modify dextran to achieve targeted effect and dispersion of biological membranes.

Benefits of technology

Dex@CoSe NPs show good antibacterial activity, can effectively inhibit and destroy biofilm, alleviate chronic wound infection caused by MRSA, and have good biocompatibility and penetration ability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004995110460000011
    Figure HDA0004995110460000011
  • Figure HDA0004995110460000021
    Figure HDA0004995110460000021
  • Figure HDA0004995110460000031
    Figure HDA0004995110460000031
Patent Text Reader

Abstract

The invention discloses glucan functionalized cobalt selenide nanoparticles as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. CoCl2, Na2SeO3 and glutathione are prepared into an ultra-small cobalt selenide nano material CoSe NPs through a one-pot method, and then glucan is modified to obtain the glucan functionalized cobalt selenide nano particles. According to the preparation method disclosed by the invention, a novel nano material-cobalt selenide nano particles (CoSe NPs) with good antibacterial activity is synthesized for the first time, and dextran (Dexat CoSe NPs) capable of targeting an extracellular polymer matrix is modified so as to realize dispersion of a biofilm. An in-vitro antibacterial experiment shows that the Dexat CoSe NPs can inhibit and destroy a biofilm and eliminate bacteria. More importantly, Dexat CoSe NPs can be used for effectively relieving chronic wound infection caused by MRSA (Methicillin-Resistant Staphylococcus Aureus). In short, the invention provides a new thought for overcoming drug-resistant bacterial biofilm related infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a dextran functionalized cobalt selenide nanoparticle and a preparation method and application thereof. Background Art

[0002] Bacterial infections are associated with severe morbidity and mortality, posing a major threat to global health. The overuse and misuse of antibiotics have led to the emergence of drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA), which could cause 10 million deaths per year by 2050. About 80% of bacterial infections are associated with biofilms, which have a dense physical structure and are rich in extracellular polymers (EPS) of polysaccharides and nucleic acids. Due to the presence of EPS, the biofilm microenvironment is hypoxic, resulting in anaerobic glycolysis, ion channel disorder, and higher acidity than healthy tissue. In addition, biofilms are also the culprit of many chronic diseases. Given that the discovery cycle of antibiotics is quite long, there is an urgent need to develop alternative antibiotic therapies that can effectively eliminate drug-resistant bacteria, especially inhibit their biofilm formation.

[0003] The rapid development of nanotechnology has provided a promising alternative solution for combating bacteria. Typical antibacterial materials reportedly include noble metals (Au, Pt, and AgNPs), transition metals (Fe, Cu, Mn, and Ni), and quantum dots. Among these nanomaterials, silver nanoparticles have become the most widely studied antibacterial agent due to their high antibacterial efficiency. However, recent studies have shown that bacteria that are initially sensitive to silver nanoparticles can become resistant to their toxic effects after repeated exposure to sub-inhibitory concentrations for a long time. In addition, nanomaterials lack sufficient bacterial capture capacity, resulting in unsatisfactory antibacterial effects. The physical properties of nanomaterials, including shape, size, and structure, can be easily designed and controlled. More importantly, the surface of nanomaterials can be modified and functionalized as needed to achieve a variety of antibacterial capabilities.

[0004] Dextran (Dex) is a polysaccharide extracted from microorganisms with high stability and biocompatibility. It is an FDA-approved polymer widely used in the biomedical field. Dextran is bound to the matrix of biofilms by extracellular enzymes (such as Streptococcus mutans glucose-derived glycosyltransferase), which uses dextran as a receptor molecule to synthesize bacterial extracellular polymer matrix dextran. Therefore, dextran-modified nanoparticles have high specificity and penetration for biofilms. Therefore, XU et al. prepared asymmetric janus-structured dextran bismuth selenide (Dex-BSe) nanoparticles targeting the extracellular polymer matrix to achieve the dissipation of drug-resistant biofilms or near-infrared (NIR) light-activated photothermal killing, respectively. Dextran has targeting to EPS; and the unique Janus structure self-driven motion of Dex-BSe enhances the photothermal killing effect. The two components work synergistically, thereby flexibly eliminating biofilm-related infections. In addition, the research team also reported an oxygen-free polymer photosensitizer (HQRB-SS-Dex) constructed with quaternary ammonium salts and dextran to potentially combat a variety of oral bacteria through APDT. The oxygen-independent polycationic photosensitizer (HQRB-SS-Dex) promotes the attachment of HQRB-SS-Dex to the bacterial surface and the penetration of bacterial biofilms, thereby more effectively utilizing the ROS generated by the photosensitizer under laser irradiation, ultimately leading to bacterial death and biofilm collapse. Although these studies can effectively target and eliminate biofilms, they all require light irradiation, cannot penetrate deep tissues, and are only effective and applicable in the treatment of superficial infections. It is difficult to eliminate infections associated with biofilms in the inner layer. Therefore, antibacterial nanoformulations that target and eliminate inner biofilms still need further research. Summary of the invention

[0005] The purpose of the present invention is to provide a dextran functionalized cobalt selenide nanoparticle and a preparation method and application thereof, so as to solve the problems existing in the above-mentioned prior art.

[0006] To achieve the above object, the present invention provides the following solutions:

[0007] One of the technical solutions of the present invention is a dextran functionalized cobalt selenide nanoparticle, which is prepared into cobalt selenide nanomaterial CoSe NPs by a one-pot method from CoCl2, Na2SeO3 and GSH, and then modified with dextran to obtain the dextran functionalized cobalt selenide nanoparticle.

[0008] The second technical solution of the present invention is a method for preparing the dextran functionalized cobalt selenide nanoparticles, comprising the following steps:

[0009] (1) CoCl2 and GSH are dissolved in dimethyl sulfoxide, the pH is adjusted to weak alkalinity, Na2SeO3 solution is added after heating, and then a one-pot reaction is carried out. After the reaction is completed, the cobalt selenide nanomaterial CoSe NPs is obtained by centrifugation and drying;

[0010] (2) Mixing the cobalt selenide nanomaterial CoSe NPs with dextran, stirring for reaction, centrifuging, and freeze-drying to obtain the dextran functionalized cobalt selenide nanoparticles.

[0011] The third technical solution of the present invention is the use of the dextran functionalized cobalt selenide nanoparticles in the preparation of drugs for preventing and treating diseases caused by bacterial infections.

[0012] A fourth technical solution of the present invention is a drug for preventing and treating diseases caused by bacterial infection, wherein the drug comprises the dextran functionalized cobalt selenide nanoparticles.

[0013] Based on the above technical solution, the present invention has the following technical effects:

[0014] The present invention synthesized for the first time a new type of nanomaterial with good antibacterial activity - cobalt selenide nanoparticles (CoSeNPs), and modified dextran (Dex@CoSe NPs) that can target the extracellular polymer matrix to achieve the dispersion of biofilms. In vitro antibacterial experiments showed that Dex@CoSe NPs can inhibit and destroy biofilms and eliminate bacteria. More importantly, Dex@CoSe NPs can effectively alleviate chronic wound infections caused by MRSA. In short, the present invention provides a new idea for overcoming infections associated with drug-resistant bacterial biofilms. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0016] Figure 1Characterization of Dex@CoSe NPs. (A) TEM of CoSe NPs. (B) TEM of Dex@CoSe NPs. (C) Zeta potential of CoSe NPs and Dex@CoSe NPs. (D) UV-visible spectrum. (E) Fluorescence spectrum. (F) Standard curve of CoSe NPs. (G) XRD of CoSe NPs and Dex@CoSe NPs. (H) Full XPS spectrum of CoSe NPs and Dex@CoSe NPs. High-resolution XPS spectrum of (I) Co 2p and (J) Se 3d in Dex@CoSe NPs. High-resolution XPS spectrum of (K) Co 2p and (L) Se3d in CoSe NPs.

[0017] Figure 2 In vitro antibacterial activity. Among them, (AC) Antibacterial activity of CoSe NPs against methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli and Pseudomonas aeruginosa. (DF) Antibacterial activity of MRSA after different treatments. (GH) Photos of MRSA after different treatments and relative activity of bacteria. (I) Quantitative analysis of (J). (J) Photos of MRSA after different treatments. (K) SEM characterization of bacterial morphology after MRSA was treated with different drugs (blue arrows indicate shrinkage and damaged cell membrane).

[0018] Figure 3 For in vitro anti-biofilm activity. Among them, (AB) photos and quantification of immature biofilm stained with crystal violet (showing the inhibitory effect of CoSe NPs on biofilm). (CD) photos and quantification of mature biofilm stained with crystal violet (showing the destructive effect of CoSe NPs on biofilm). (EF) photos and quantification of immature biofilm stained with crystal violet (showing the inhibitory effect of different drugs on biofilm). (G) 3D confocal images of immature MRSA biofilm stained with SYTO 9 after different treatments. (H) Quantification of (G).

[0019] Figure 4 In vitro anti-biofilm. (A) Schematic diagram of the treatment process of chronic wounds in infected mice. (B) Representative diagram of the wound healing process in infected mice. (C) Traces of wound closure in mice. (D) Quantitative analysis of the rate of change of wound area in mice. (E) Changes in temperature of wounds in mice. (F) Rate of change of body weight in mice. (G) H&E staining, Masson staining, and immunohistochemical staining of CD31, TNF-α, and IL-10 in damaged skin on the 9th day of treatment.

[0020] Figure 5The biosafety evaluation of Dex@CoSe NPs. (AC) Cytotoxicity of different concentrations of Dex@CoSe NPs on Beas-2B, HK-2 and Lx-2. (D) Quantitative analysis and photos of hemolysis of erythrocytes incubated with different concentrations of Dex@CoSe NPs. (E) Blood routine test of mice on day 11. DETAILED DESCRIPTION

[0021] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0022] It should be understood that the terms described in the present invention are only for describing special embodiments and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. Each smaller range between the intermediate value in any stated value or stated range and any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0023] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0024] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present application description and examples are exemplary only.

[0025] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0026] The technical solutions described in the present invention, unless otherwise specified, are all conventional solutions in the art, and the reagents or raw materials used, unless otherwise specified, are purchased from commercial channels or are publicly available.

[0027] The embodiment of the present invention provides a dextran functionalized cobalt selenide nanoparticle, wherein CoCl2, Na2SeO3 and GSH are used to prepare cobalt selenide nanomaterial CoSe NPs by a one-pot method, and then dextran is modified to obtain the dextran functionalized cobalt selenide nanoparticle.

[0028] Selenium (Se) is one of the essential trace elements for the human body and plays a vital role in maintaining human health, including wound healing. Supplementation of selenium is beneficial to wound healing and even reduces the risk of bacterial infection. Cobalt is an important transition metal that has attracted the interest of researchers due to its low cost, earth abundance and strong stability. It is a trace element necessary for cell metabolism and plays a very important role in the entire life process of animals and plants. Therefore, the present invention designs and synthesizes ultra-small cobalt selenide nanoparticles (CoSe NPs), and modifies Dex to obtain Dex@CoSe NPs, which can specifically inhibit and destroy biofilms and exert a bactericidal effect by shrinking bacterial cell walls. In addition, the in vivo wound infection model also shows that Dex@CoSe NPs can promote angiogenesis, reduce inflammatory responses and promote wound healing, and has good biocompatibility.

[0029] The embodiment of the present invention also provides a method for preparing the dextran functionalized cobalt selenide nanoparticles, comprising the following steps:

[0030] (1) CoCl2 and GSH are dissolved in dimethyl sulfoxide, the pH is adjusted to weak alkalinity, Na2SeO3 solution is added after heating, and then a one-pot reaction is carried out. After the reaction is completed, the cobalt selenide nanomaterial CoSe NPs is obtained by centrifugation and drying;

[0031] (2) Mixing the cobalt selenide nanomaterial CoSe NPs with dextran, stirring for reaction, centrifuging, and freeze-drying to obtain the dextran functionalized cobalt selenide nanoparticles.

[0032] In some specific embodiments, the molar ratio of CoCl2, GSH and Na2SeO3 is 1:4:(11-12); and the heating temperature is 90-100°C.

[0033] In some specific embodiments, the one-pot reaction is carried out at a temperature of 120 to 150° C. and for a time of 18 to 24 hours.

[0034] In some specific embodiments, the mass ratio of the cobalt selenide nanomaterial CoSe NPs to dextran is (2-4):1.

[0035] In some specific embodiments, the mass ratio of the cobalt selenide nanomaterial CoSe NPs to dextran is 2:1.

[0036] In some specific embodiments, the step of adjusting the pH to a weakly alkaline state comprises adjusting the solution to pH 9 using 1 M sodium hydroxide.

[0037] In some specific embodiments, the concentration of the Na2SeO3 solution is 0.59 M and the volume is 5 mL; the Na2SeO3 solution is purged with argon before being added.

[0038] In some specific embodiments, the stirring reaction is: stirring at room temperature overnight.

[0039] The embodiment of the present invention also provides the use of the dextran functionalized cobalt selenide nanoparticles in the preparation of drugs for preventing and treating diseases caused by bacterial infections.

[0040] The embodiment of the present invention further provides a medicine for preventing and treating diseases caused by bacterial infection, wherein the medicine comprises the dextran functionalized cobalt selenide nanoparticles.

[0041] In some specific embodiments, the bacteria comprises methicillin-resistant Staphylococcus aureus.

[0042] Example 1

[0043] 1 Synthesis

[0044] CoCl2·6H2O (0.0618 g, 0.26 mmol) and glutathione (GSH, 0.32 g, 1.04 mmol) were added to a reaction tube (100 ml) containing 20 mL of dimethyl sulfoxide. The solution was adjusted to pH 9 with sodium hydroxide (1 M), and the solution changed from a blue suspension to a dark green suspension, and the mixture was heated to 95°C. Then, an argon-purged Na2SeO3 solution (0.59 M, 5 mL) was injected and then heated to 140°C for 20 hours. After the reaction was completed, it was naturally cooled to 25°C and the solution was black. Then it was centrifuged and washed 2-3 times. The precipitate was dried into powder in a vacuum oven at 25°C to obtain cobalt selenide nanoparticles (CoSeNPs).

[0045] 20 mg of CoSe NPs particles were dissolved in 4 mL of pure water, and further mixed with 1 mL of 10 mg / mL dextran (Dex) solution. The reaction solution was stirred at room temperature for 10-12 h, then centrifuged at 10000 rpm and washed with pure water 3 times. The precipitate was collected and freeze-dried to obtain Dex@CoSe NPs (1:2).

[0046] The same can be done for Dex@CoSe NPs(1:4).

[0047] 2 Characterization

[0048] The prepared nanozymes were characterized using a variety of methods. TEM measurements were performed on a TECNAI G2 equipped with EDS at 200 kV. Atomic structure images were characterized using a TEMARM-200 (JEOL, Tokyo, Japan) transmission electron microscope operated at 200 kV. X-ray photoelectron spectroscopy (XPS) analysis was performed by a ThermoVG Scientific ESCALAB 250 spectrometer. Ultraviolet visible (UV-vis) absorption spectra were recorded using a UV-2600 spectrophotometer (Shimadzu Corporation).

[0049] CoSe NPs were synthesized by solvothermal method, and the size and shape of cobalt selenide quantum dots were characterized by transmission electron microscopy (TEM). Figure 1 A in the figure shows that CoSe NPs are uniformly dispersed dots with a particle size of about 2-3 nm. CoSe NPs were reacted with dextran (Dex) at a ratio of 4:1 and 2:1, respectively, to obtain Dex@CoSe NPs (1:2) and Dex@CoSe NPs (1:4). Zeta potential tests showed that CoSe NPs, Dex@CoSe NPs (1:2) and Dex@CoSe NPs (1:4) all had high negative potentials, indicating that the synthesized materials had good stability ( Figure 1 The phase structures of Dex@CoSe NPs (1:2) and CoSe NPs were analyzed by X-ray diffraction (XRD) patterns ( Figure 1 G). The XRD patterns of Dex@CoSe NPs and CoSe NPs are very similar to those of the standard CoSe hexagonal phase (JCPDS card number: 89-2004). In addition, X-ray photoelectron spectroscopy (XPS) studies were further performed to gain insight into the chemical and electronic structures of Dex@CoSe NPs (1:2). Figure 1 As shown in the figure, the signals of Co, O, N, C, S, Co and Se can be clearly detected. In order to further analyze the changes in functional groups, high-resolution spectral analysis of Co 2p and Se 3d was performed. The peak of Co-Se is in the high-resolution narrow spectrum of Co 2p. Figure 1 I and J) can be well matched, and there are two obvious peaks at 780.0 and 795.4 eV, which correspond to the Co 2p3 / 2 and Co 2p1 / 2 orbital peaks, respectively, and the peaks attributed to Se 3d3 / 2 and Se 3d5 / 2 are located at 55.6 and 55.0 eV respectively [40, 41] ( Figure 1 K, L in the middle). UV absorption spectrum ( Figure 1(D) shows that at 200-800nm ​​wavelength, Dex, CoSe NPs, Dex@CoSe NPs (1:2) and Dex@CoSe NPs (1:4) all have absorption. Figure 1 E) shows that with 365nm as the excitation wavelength, Dex@CoSe NPs (1:2) and Dex@CoSe NPs (1:4) contain emission peaks of both CoSe NPs and Dex. The above results indicate the successful synthesis of CoSe NPs and the possible connection between CoSe NPs and Dex. Subsequently, the present invention uses UV-visible spectroscopy to quantitatively analyze the drug loading ( Figure 1 (F), the CoSe NPs loading rate in Dex@CoSe NPs (1:4) is 49.54%, and the Dex grafting rate is 50.46%. The CoSe NPs loading rate in Dex@CoSe NPs (1:2) is 23.09%, and the Dex grafting rate is 76.91%.

[0050] Example 2

[0051] 1Minimum inhibitory concentration (MIC)

[0052] The minimum inhibitory concentration of different treatments for different strains was determined by the Clinical Laboratory Standards Institute broth microdilution method. First, the bacteria were cultured overnight in LB medium at 37°C in a shaker (180-200 rpm) until the logarithmic growth phase was reached. The precipitate was then collected by centrifugation and washed three times with 0.85% sodium chloride solution. The concentration of suspended bacteria was measured by the optical density (OD 600 ) was used to determine the bacterial solution. The bacterial solution was diluted with culture medium to 1×10 6 CFU / mL. 100 μL of these solutions were added to 96-well plates containing different concentrations of drugs (100 μL) to give a final bacterial concentration of approximately 5 × 10 5 CFU / mL. The bacteria were cultured at 37°C for 24 h, and the OD of the bacterial suspension was measured using a multifunctional microplate reader. 600 The minimum inhibitory concentration (MIC) was calculated from the values. The minimum inhibitory concentration was determined as the treatment concentration at which no microbial growth was observed. Each test was repeated 3 times.

[0053] 2. Dilution plate method

[0054] The different materials were diluted to 5 × 10 5 CFU / mL of MRSA (n=3) was diluted with LB medium to a volume of 200 μL and added to a 96-well plate. After culturing for 24 h, the suspension was diluted with PBS buffer by 10 5times, and spread 50 μL of the bacterial solution on LB agar plates, culture at 37°C for 18-24 hours, take pictures of the LB agar plates and count the colonies.

[0055] 3 Oxford Cup Experiment

[0056] Dex@CoSe NPs (1:2), Dex@CoSe NPs (1:4), Dex, and CoSe NPs were added to PBS to a final concentration of 500 μg / mL, followed by the addition of 1×10 6 Mix the MRSA at 100 CFU / mL, place the Oxford cup vertically on the culture dish with agar, then pipette 10 μL of the mixture into the Oxford cup, place it in a 37°C incubator, and take pictures after 24 hours.

[0057] 4 Scanning electron microscopy analysis of bacterial morphology

[0058] The bacterial suspension (5×10 5 CFU / mL) and 300μg / ml of CoSe NPs, Dex@CoSe NPs (1:2) or Dex@CoSe NPs (1:4) were treated at 37°C for 3 hours, and then MRSA bacteria were washed twice with PBS (3500rpm, 5min). Then, each group of samples was fixed in 2.5% glutaraldehyde solution at 4°C for 4 hours. Then, they were washed three times with PBS buffer, and dehydrated with different concentrations of ethanol (20%, 40%, 60%, 80% and 100%) for 5 minutes. The samples were air-dried to dehydrate the bacteria and further observed with a scanning electron microscope.

[0059] The 96-well plate method was used to evaluate the minimum inhibitory concentration (MIC) of the synthesized CoSe NPs, Dex@CoSe NPs (1:2) and Dex@CoSe NPs (1:4) against bacteria. Methicillin-resistant Staphylococcus aureus (MRSA), Escherichia coli (E. coli) and Pseudomonas aeruginosa (Pseudomonas aeruginosa) were used as models for broad-spectrum antibacterial tests. Figure 2 The AC showed that CoSe NPs had inhibitory activity against both MRSA and E. coli, and its inhibitory activity was concentration-dependent within a certain concentration range. In view of the better antibacterial activity against MRSA than E. coli, MRSA was selected as the model for subsequent experiments. Figure 2DF in the figure shows that compared with Dex and CoSe NPs, Dex@CoSe NPs (1:2) and Dex@CoSe NPs (1:4) have higher antibacterial activity, but Dex@CoSe NPs (1:2) and Dex@CoSe NPs (1:4) have similar antibacterial activities, with MIC values ​​of 150 μg / mL. Figure 2 Middle G) and the Oxford Cup Experiment ( Figure 2 The antibacterial activity was observed and the above two experimental results were quantified ( Figure 2 H, I). Figure 2 As can be seen in G, Dex@CoSe NPs (1:2) and Dex@CoSe NPs (1:4) have almost no colonies, but Figure 2 It can be found that Dex@CoSe NPs (1:2) have fewer colonies than Dex@CoSe NPs (1:4). Therefore, subsequent safety and in vivo antibacterial activity experiments were conducted with Dex@CoSe NPs (1:2).

[0060] Based on the good in vitro antibacterial activity of Dex@CoSe NPs (1:2), the present invention further studied the morphological changes of Staphylococcus aureus after different treatments by scanning electron microscopy to better understand the antibacterial results. Figure 2 As shown in Figure K, untreated MRSA presents a typical round structure with a smooth surface and intact cell wall. After treatment with CoSe NPs and Dex@CoSe NPs, the surface of MRSA is wrinkled, and the surface of MRSA treated with Dex@CoSe NPs has more obvious folding and damage, and the cell wall surface is severely damaged, indicating that compared with CoSeNPs, Dex@CoSeNPs (1:2) has better antibacterial activity.

[0061] Example 3

[0062] 1 In vitro inhibition or destruction of biofilm analysis

[0063] In order to detect the ability of CoSe NPs and Dex@CoSe NPs (1:2) to inhibit biofilm formation, 1 mL of 1×10 8CFU / mL of MRSA bacterial suspension was cultured at 37°C for 24 hours, and then the old culture medium was replaced with a culture medium containing PBS, CoSeNPs, and Dex@CoSe NPs (1:2). After different treatments, the cells were washed with PBS three times, the biofilm was fixed with 95% methanol, and stained with 0.1% crystal violet for 30 minutes. After washing with PBS until the supernatant was colorless, it was air-dried and photographed. The dye was dissolved with 33% acetic acid, and the absorbance of the solution at 590nm was measured by an enzyme labeling instrument. In addition, the biofilm formed on the confocal dish was treated as described above, stained with SYTO 9 for 30 minutes, and then imaged with a confocal microscope.

[0064] To evaluate the effect of destroying mature biofilm, the bacterial suspension was cultured in LB medium for 48 h to form mature biofilm, and then treated with PBS, CoSe NPs and Dex@CoSe NPs (1:2) for 24 h. The residual biofilm was identified by crystal violet staining.

[0065] 2MTT assay

[0066] The cytotoxicity of Dex@CoSe NPs (1:2) on different cell lines was investigated by MTT assay. Cells (Beas-2B, HK-2 and Lx-2 cell lines) were seeded into 96-well plates at a density of 4000-5000 cells / well with 100 μL of culture medium. After 24 h of incubation, the culture medium was replaced with 100 μL of fresh culture medium containing different concentrations of Dex@CoSe NPs (1:2), and the cells were incubated for another 24 h. After 24 h of treatment, MTT solution was added to each well, followed by incubation at 37 °C for 4 h. The culture medium was aspirated, 150 μL of DMSO was added to dissolve the blue formazan in the living cells, and the absorbance was measured at 570 nm using a microplate reader. Cells incubated with culture medium alone were considered to have 100% viability. Cell viability (%) = OD value of each treatment group / OD value of the control group × 100%.

[0067] 3. Hemolysis test

[0068] Commercially purchased 4% fresh red blood cells (RBC, 5 mL) were centrifuged at 3500 rpm for 5 min and gently washed 3 times with sterile PBS. 100 μL of different concentrations of Dex@CoSe NPs (1:2) were added to 300 μL of red blood cells and incubated at 37 °C for 4 hours. At the end of the incubation, the solution was centrifuged at 3500 rpm for 5 min, and the hemolytic activity was measured at 540 nm using a microplate reader. Triton X-100 (0.1% in PBS), which can completely lyse red blood cells, was used as a positive control, while PBS was used as a negative control. Red blood cell hemolysis (HR) was calculated according to the following formula:

[0069] Hemolysis rate (%) = (absorbance of sample - absorbance of negative control) / (absorbance of positive control - absorbance of negative control) × 100%.

[0070] Most bacteria can form biofilms on different surfaces. Bacterial biofilms have a dense physical structure and are rich in extracellular polymers of polysaccharides and nucleic acids, which can resist the penetration of antimicrobial drugs, allowing bacteria to survive in harsh environments, leading to drug resistance and repeated infections. Based on the good antibacterial activity of Dex@CoSe NPs (1:2), the present invention evaluated the anti-biofilm activity of Dex@CoSe NPs (1:2).

[0071] First, the ability of CoSe NPs to inhibit biofilm formation was evaluated. The biofilms treated with different concentrations of CoSe NPs were stained with crystal violet, and then the absorbance was measured at a wavelength of 590 nm for quantification. It was found that with the increase in the concentration of CoSe NPs, the color of the biofilm gradually became lighter, indicating that CoSe NPs can inhibit the growth of biofilms ( Figure 3 A, B). The present invention then evaluated its ability to destroy biofilm ( Figure 3 In (C, D), it can be found that the color of the CoSe NPs group is lighter than that of the Control group, which indicates that CoSe NPs can destroy the biofilm.

[0072] Since the antibacterial activity of Dex@CoSe NPs (1:2) is better than that of CoSe NPs, the present invention uses crystal violet staining to compare the ability of CoSe NPs and Dex@CoSe NPs (1:2) to inhibit biofilm formation. Figure 3 E and F) show that Dex@CoSe NPs (1:2) have a better ability to inhibit biofilm formation than CoSe NPs. Since PI can mark dead bacteria with damaged bacterial membranes, because it can reach the cell nucleus and embed into DNA to produce red fluorescence, and SYTO 9 can enter all bacteria. Generally speaking, when the two dyes penetrate into bacteria, the fluorescence intensity of SYTO 9 (green) decreases. Therefore, bacteria with intact cell membranes show green fluorescence, while damaged cell membrane structures mainly show red fluorescence. Therefore, the present invention uses three-dimensional confocal scanning microscopy to analyze the live / dead staining of biofilms ( Figure 3 G), and the fluorescence intensity of the stained biofilm was quantified by Image J ( Figure 3H). The results are consistent with crystal violet staining. The biofilm treated with Dex@CoSe NPs (1:2) has less green fluorescence and shows a completely intact red color, which indicates that Dex@CoSe NPs (1:2) damages the cell membrane and inhibits the formation of biofilm. The above results show that Dex@CoSe NPs (1:2) has good anti-biofilm activity and is more excellent than CoSe NPs.

[0073] The biocompatibility of Dex@CoSe NPs (1:2) was evaluated by MTT method. The results showed that the cell survival rate was still 80% when the concentration of Dex@CoSe NPs (1:2) was 150 μg / mL ( Figure 5 AC). Then, the effect of Dex@CoSe NPs (1:2) on the rupture and lysis of red blood cells (RBC) was studied by hemolysis experiment ( Figure 5 D). After incubation with high concentration (300 μg / mL) of Dex@CoSe NPs (1:2), the hemolysis rate was extremely low <5%. The above results indicate that there is no obvious toxicity to normal mammalian cells at high concentrations. In addition, in chronic wound infection, there was no significant difference in routine blood tests between the treated and untreated groups ( Figure 5 (E), demonstrating that Dex@CoSe NPs (1:2) have almost no side effects within a certain concentration range and have good biocompatibility.

[0074] Example 4

[0075] 1 Establishment of mouse wound infection model

[0076] The back of the ICR mouse was depilated with a depilatory agent, and a circular wound with a diameter of about 10 mm was made with ophthalmic scissors. 50 μL of 2×10 8 CFU / mL MRSA was used to construct an infection model. The mice were then randomly divided into 5 groups (n=5) and given medication every other day. Each group of mice was given 50μL PBS, 2.5mg / kg CoSe NPs, Dex@CoSe NPs (1:2) or vancomycin on the back. The mice were weighed, their body temperature, wound area, and photographed. On the 11th day, fresh whole blood was collected to assess in vivo biosafety. The mice were then killed by cervical dislocation, and sections of different wounds were subjected to H&E staining, Masson staining, and immunohistochemistry staining.

[0077] In wound care, MRSA infection is a major clinical challenge. Based on the good antibacterial and anti-biofilm formation capabilities of Dex@CoSe NPs (1:2) in vitro, a chronic MRSA wound infection model was constructed in the present invention to evaluate the ability of Dex@CoSe NPs (1:2) to promote the healing of MRSA-infected wounds. A circular incision (about 10-12 mm in diameter) was constructed on the back skin of ICR mice. Sterile saline was dripped into the uninfected group, and 2×10 8 CFU / mL MRSA bacterial suspension 50μL (recorded as the first day), and then cultured for two days to form a biofilm, and the drug was given every two days, and the treatment was terminated on the 11th day. The wound infection group was dripped with 3mg / kg PBS, Van, CoSe NPs and Dex@CoSe NPs (1:2) to treat the infected wounds. In order to observe the treatment effects of different groups, the temperature, weight and skin wound healing pictures of the mice were recorded on the 1st, 3rd, 5th, 7th, 9th and 11th days after treatment ( Figure 4 (A).

[0078] First, the evaluation was performed by clinically assessing health and disease symptoms, i.e., visual inspection of the wounds and monitoring of the weight and activity level of the mice. Visual inspection of the wound sites confirmed that the wounds formed scabs and gradually decreased in size during the treatment process, and the wounds of mice treated with Dex@CoSe NPs (1:2) were almost completely healed on day 11 ( Figure 4 During the treatment, the wound surface temperature remained basically stable ( Figure 4 E), but the body weight of the PBS group decreased ( Figure 4 Inflammation and tissue formation are important processes in wound healing. In order to study these subtle changes in infected wounds, the present invention uses H&E, Masson, CD31, TNF-α and IL-10 ( Figure 4(G) The wound was histologically analyzed. Therefore, on the 11th day, the present invention took the tissue around the wound for histomorphological analysis. H&E staining showed that the Dex@CoSe NPs (1:2) group had significantly fewer inflammatory cells than the control group, indicating that Dex@CoSe NPs (1:2) can promote skin regeneration. The production of collagen in dermal fibroblasts is also important for wound healing. The results of Masson staining showed that the collagen staining intensity of the wound surface in the Dex@CoSe NPs (1:2) group was significantly enhanced, indicating that there was a large amount of collagen fiber deposition in the Dex@CoSe NPs (1:2) group. In addition, the present invention also performed immunohistochemical analysis. Since CD31 is mainly expressed in tight junctions between skin endothelial cells and is involved in the formation of blood vessels, angiogenesis is crucial to tissue regeneration by providing sufficient oxygen and nutrients, as well as promoting the transport of cytokines and cell migration. Therefore, the present invention performs CD31 immunostaining on the wound surface after different treatments to show the level of angiogenesis. After 11 days of treatment, immunohistochemical staining of the vascular endothelial cell marker CD31 showed stronger CD31 staining in the Dex@CoSe NPs (1:2) group, suggesting further stimulation of angiogenesis during wound healing. Inflammation is a key stage in wound healing. However, severe inflammatory responses caused by bacterial infection can delay the wound repair process. Therefore, the present invention performed immunostaining of TNF-α and IL-10 on the wound surface. The results showed that compared with the PBS group, the expression of the pro-inflammatory factor TNF-α in the group treated with Dex@CoSe NPs (1:2) was significantly reduced, while the expression of the anti-inflammatory factor IL-10 was increased, which is helpful for the repair of skin tissue. The above results show that Dex@CoSe NPs (1:2) has a long-lasting and effective antibacterial effect on bacterial skin wound infection, and promotes the healing of MRSA wounds.

[0079] In summary, the present invention successfully constructed a new type of nanomaterial, namely CoSe NPs, through a one-pot method. It has a spherical nanostructure and a very small particle size of 2-3nm. In addition, it has good antibacterial and anti-biofilm activity. Therefore, the present invention modified Dex to obtain Dex@CoSe NPs, thereby targeting biofilms. The present invention found that after modification with Dex, its antibacterial and anti-biofilm activity increased. Finally, the present invention confirmed that Dex@CoSe NPs showed healing properties in the skin injury model of MRSA infection, such as increased wound closure rate, increased collagen, reduced inflammation and enhanced angiogenesis. The above results show that Dex@CoSe NPs is an antibacterial agent with excellent antibacterial and anti-biofilm application performance, and has good biocompatibility. In short, this method provides opportunities for non-antibiotic drug therapy, targeted therapy, and antibacterial therapy design.

[0080] Obviously, the above embodiments of the present invention are merely examples for clearly explaining the present invention, and are not intended to limit the implementation methods of the present invention. For ordinary technical users in the relevant field, other different forms of changes or modifications can be made on the basis of the above description. It is not necessary and impossible to list all the implementation methods here. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the claims of the present invention.

Claims

1. A dextran functionalized cobalt selenide nanoparticle, characterized in that: Cobalt selenide nanomaterial CoSe NPs are prepared from CoCl2, Na2SeO3 and glutathione by a one-pot method, and then dextran is modified to obtain the dextran functionalized cobalt selenide nanoparticles.

2. The method for preparing dextran functionalized cobalt selenide nanoparticles according to claim 1, characterized in that: The following steps are involved: (1) CoCl2 and glutathione are dissolved in dimethyl sulfoxide, the pH is adjusted to weak alkalinity, Na2SeO3 solution is added after heating, and then a one-pot reaction is carried out. After the reaction is completed, the cobalt selenide nanomaterial CoSe NPs is obtained by centrifugation and drying; (2) mixing the cobalt selenide nanomaterial CoSe NPs with dextran, stirring for reaction, centrifuging, and freeze-drying to obtain the dextran functionalized cobalt selenide nanoparticles.

3. The preparation method according to claim 2, characterized in that: The molar ratio of CoCl2, GSH and Na2SeO3 is 1:4:(11-12); the heating temperature is 90-100°C.

4. The preparation method according to claim 2, characterized in that: The one-pot reaction has a temperature of 120 to 150° C. and a reaction time of 18 to 24 hours.

5. The preparation method according to claim 2, characterized in that: The mass ratio of the cobalt selenide nanomaterial CoSe NPs to dextran is (2-4):

1.

6. The preparation method according to claim 6, characterized in that: The mass ratio of the cobalt selenide nanomaterial CoSe NPs to dextran is 2:

1.

7. Use of the dextran functionalized cobalt selenide nanoparticles as claimed in claim 1 in the preparation of drugs for preventing and treating diseases caused by bacterial infections.

8. A drug for preventing and treating diseases caused by bacterial infection, characterized in that: The drug comprises the dextran functionalized cobalt selenide nanoparticles according to claim 1.

9. The drug according to claim 8, characterized in that The bacteria include methicillin-resistant Staphylococcus aureus.

Citation Information

Patent Citations

  • Functional nano-selenium probe as well as preparation method of functional nano-selenium probe and application of functional nano-selenium probe in preparation of medicine for diagnosing and treating bacterial infection

    CN107179403A

  • CoSe@BSA nanoparticle drug composition as well as preparation method and application thereof

    CN113209046A

  • Metal selenium-based biological catalytic material as well as preparation method and application thereof

    CN115624980A

  • Sipunculus nudus polypeptide functionalized iridium oxide nano-enzyme with antibacterial effect as well as preparation method and application of sipunculus nudus polypeptide functionalized iridium oxide nano-enzyme

    CN116327802A

  • Kit for treating sepsis and / or any systemic (SIRS) or damaging cellular hyperinflammation

    US20180185443A1

Cited By

  • GSH-Fe3-XSe3 nano material as well as preparation method and application thereof

    CN119970654A